ReviewCureus2026
Life Course Vaccination Continuum (LCVAC): An Expert Consensus on Life Course Vaccination in India.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
India's immunization program focuses predominantly on children, leaving adults vulnerable to vaccine-preventable diseases (VPDs). The COVID-19 pandemic further disrupted routine vaccination. A life course approach (LCA) is needed to address these gaps. However, implementation of adult vaccination programs in low- and middle-income countries (LMICs) remains challenged by inequities in healthcare access, infrastructural limitations, and variable awareness regarding adult immunization. A 16-member expert panel from pulmonology, geriatrics, oncology, obstetrics, nephrology, diabetology, and life sciences reviewed literature (2014-2023) from MEDLINE, Scopus, and Cochrane databases. Using a structured, evidence-based grading approach, the panel formulated consensus recommendations for adult vaccination in India. The Life Course Vaccination Continuum (LCVAC) proposes three target groups: adults aged 18-59 years with comorbidities; elderly ≥60 years with or without comorbidities; and healthy adults aged 18-60 years. Key recommended vaccines include Tdap (every 10 years), influenza (annual), pneumococcal (PCV13/PPSV23 series), zoster (for ≥50 years), hepatitis B, meningococcal, and hepatitis A (risk-based). Major barriers identified include vaccine hesitancy, cost, access limitations, and inadequate provider prioritization. Life Course Vaccination Continuum provides the first comprehensive expert consensus on life course vaccination in India. The framework is intended to complement broader public health strengthening efforts, and its successful implementation will require vaccine awareness campaigns, healthcare professional education, equitable access strategies, and the establishment of dedicated adult vaccination centers nationwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.